Table 2 Clinicopathological characteristics of 229 patients with type 1 gastric NETs
From: Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study
Patient features | No. of patients | % |
|---|---|---|
Sex | ||
Male | 93 | 40.6% |
Female | 136 | 59.4% |
Main symptoms | ||
Abdominal distension | 59 | 25.8% |
Abdominal pain | 46 | 20.1% |
Belching | 21 | 9.2% |
Postprandial fullness | 20 | 8.7% |
Dizziness | 18 | 7.9% |
Lower limb pain or numbness | 5 | 2.2% |
Other symptoms | 68 | 29.7% |
Asymptomatic | 38 | 16.8% |
Number of lesions | ||
Single | 47 | 20.5% |
Multiple | 166 | 72.5% |
Maximum diameter of tumor (cm) | ||
< 0.5 | 63 | 27.5% |
0.5–0.9 | 89 | 38.9% |
1.0–1.9 | 35 | 15.3% |
≥ 2.0 | 9 | 3.9% |
Unknown | 33 | 14.4% |
Tumor shape | ||
Polypoid | 197 | 86.0% |
Erosion or ulcer | 6 | 2.6% |
Coarse granular | 5 | 2.2% |
Polyp with erosion | 12 | 5.3% |
Unknown | 9 | 3.9% |
Depth of invasion (pathological) | ||
Mucosa | 89 | 38.9% |
Submucosa | 47 | 20.5% |
Muscularis propria | 3 | 1.3% |
Unknown | 90 | 39.3% |
Histological grade | ||
NET G1 | 159 | 69.4% |
NET G2 | 60 | 26.2% |
NET G3 | 0 | 0 |
Unknown | 10 | 4.4% |
Tumor stage | ||
Stage I | 160 | 69.9% |
Stage II | 30 | 13.1% |
Stage III | 3 | 1.3% |
Stage IV | 2 | 0.9% |
Unknown | 34 | 14.8% |
Comorbidities | ||
Anemia | 85 | 39.7% |
Hashimoto’s thyroiditis | 58 | 29.3% |
Other autoimmune diseases | 9 | 6.4% |
Other malignant tumors | 12 | 9.0% |